Correlation between SPARC expression and efficacy of nab-paclitaxel for advanced gastric cancer refractory to fluoropyrimidine: An exploratory analysis of a phase II trial, CCOG1303

被引：0
|
作者：
Kobayashi, D. [1 ]
Enomoto, A. [2 ]
Mochizuki, Y. [3 ]
Matsui, T. [4 ]
Nakayama, H. [5 ]
Kawase, Y. [6 ]
Ishigure, K. [7 ]
Shikano, T. [8 ]
Torii, K. [9 ]
Kodera, Y. [1 ]
机构：
[1] Nagoya Univ, Grad Sch Med, Gastroenterol Surg, Nagoya, Aichi, Japan
[2] Nagoya Univ, Grad Sch Med, Pathol, Nagoya, Aichi, Japan
[3] Komaki Municipal Hosp, Dept Surg, Komaki, Japan
[4] Aichi Canc Ctr Hosp, Dept Surg, Okazaki, Aichi, Japan
[5] Natl Hosp Org, Dept Surg, Nagoya Med Ctr, Nagoya, Aichi, Japan
[6] Tosei Gen Hosp, Dept Surg, Seto, Japan
[7] Konan Kosei Hosp, Dept Surg, Konan, Japan
[8] Yokkaichi Municipal Hosp, Dept Surg, Yokaichi, Japan
[9] Nakatsugawa Municipal Gen Hosp, Dept Surg, Nakatsugawa, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
696P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] International phase II trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients with locally advanced pancreatic cancer (LAPC): LAPACT
    Philip, P.
    Kayitalire, L.
    Nydam, T.
    Penenberg, D.
    Hammel, P.
    ANNALS OF ONCOLOGY, 2015, 26
  • [42] Biomarker Analyses from a Phase II Trial of Nab-Paclitaxel/Carboplatin vs Emcitabine/Carboplatin in Advanced Squamous Cell Lung Cancer
    Yang, Jin-Ji
    Ben, Xiao-Song
    Huang, Cheng
    Song, Yong
    Cheng, Ying
    Chen, Gongyan
    Yan, Hong-Hong
    Zhou, Qing
    Chen, Hua-Jun
    Zhang, Xu-Chao
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S656 - S656
  • [43] Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer
    Huang, Liang
    Chen, Sheng
    Yao, Ling
    Liu, Guangyu
    Wu, Jiong
    Shao, Zhiming
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2015, 10 : 1969 - 1975
  • [44] A phase II study of FOLFOX combined with nab-paclitaxel in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: a Big Ten Cancer Research Consortium trial
    Dreyer, Marie S.
    Mulcahy, Mary
    Kocherginsky, Masha
    Chen, Yolande
    Hochster, Howard S.
    Kasi, Pashtoon M.
    Kircher, Sheetal
    Lou, Emil
    Ma, Yangruijue
    Uboha, Nataliya, V
    Benson III, Al B.
    ONCOLOGIST, 2024, 29 (12):
  • [45] Correlation of SPARC, ER, PR, and HER2 tumor with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab-paclitaxel
    Inhorn, R. C.
    Daniel, B.
    Daniel, D.
    Naot, Y.
    Zubkus, J.
    Lane, C.
    Trieu, V.
    Knauer, D.
    Desai, N.
    Yardley, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] A phase II study of S-1, oxaliplatin, and nab-paclitaxel, and itraconazole aimed at conversion surgery for advanced and recurrent gastric cancer.
    Nakamoto, Yoshihiko
    Tsubamoto, Hiroshi
    Sawazaki, Miyuki
    Kakuno, Ayako
    Sonoda, Takashi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane
    Hara, Hiroki
    Mizukami, Takuro
    Minashi, Keiko
    Nishina, Tomohiro
    Takahashi, Naoki
    Amanuma, Yusuke
    Nakasha, Akio
    Takahashi, Masaki
    Nakajima, Takako Eguchi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [48] Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).
    Lacy, Jill
    Portales, Fabienne
    Hammel, Pascal
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Kim, Edward Jae-hoon
    Dowden, Scot D.
    Borg, Christophe
    Sastre, Javier
    Bathini, Venu Gopal
    Terrebonne, Eric
    Lopez-Trabada, Daniel
    Rivera, Fernando
    Asselah, Jamil
    Damiani, Azzurra
    Hwang, Jimmy J.
    Ong, Teng Jin
    Nydam, Thom
    Li, Jack Shiansong
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [49] The NICE Salvage Study: A Phase II Trial of Weekly Nab-Paclitaxel in the Salvage Setting for Advanced Non-Small Cell Lung Cancer
    Niwa, Takashi
    Yoshioka, Hiroshige
    Hata, Akito
    Azuma, Koichi
    Tajima, Manabu
    Morita, Mitsunori
    Kogure, Yoshihito
    Akamatsu, Hiroaki
    Ishida, Tadashi
    Katakami, Nobuyuki
    Hoshino, Tomoaki
    Takenoyama, Mitsuhiro
    Takahashi, Kazuhisa
    Kaneda, Hiroyasu
    Tomioka, Hiromi
    Saka, Hideo
    Ando, Masahiko
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1078 - S1079
  • [50] Impact of SPARC expression level on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: A pooled analysis from prospective clinical and translational trials.
    Ormanns, Steffen
    Haas, Michael
    Baechmann, Sibylle
    Remold, Anna
    Quietzsch, Detlef
    Clemens, Michael R.
    Bentz, Martin
    Schoppmeyer, Konrad
    Kruger, Stephan
    Kirchner, Thomas
    Heinemann, Volker
    Boeck, Stefan Hubert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345